.png){kind=icon}
.png){kind=icon}
Return
Menin in normal and malignant megakaryopoiesis
.png){kind=icon}
PRE
AI
J
S
DOI：10.1016/j.ccell.2026.06.012.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Severe thrombocytopenia is a known complication of menin inhibitor therapy; however, the mechanism underlying this effect is unknown. In this issue of Cancer Cell, Wen et al. demonstrate that menin is a key component of normal megakaryopoiesis and establish menin as a therapeutic vulnerability in myeloproliferative neoplasms.
Journal
IF:
44.5
Papers:
413
Citations:
5.6W
Organization
Cited Papers